OmpA and Asp14 in vaccine compositions and as diagnostic targets
US-10039815-B2 · Aug 7, 2018 · US
Vaccines and diagnostics for the ehrlichioses
US10131705B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10131705-B2 |
| Application number | US-201715814942-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 16, 2017 |
| Priority date | Jan 10, 2008 |
| Publication date | Nov 20, 2018 |
| Grant date | Nov 20, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inducing an immune response against Ehrlichia chaffeensis in a mammalian subject comprising administering to said subject a therapeutically effective amount of composition comprising an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; or SEQ ID NO: 11, or an amino acid sequence that is at least 95% identical to SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; or SEQ ID NO: 11, wherein the polypeptide is no more than 50 amino acids in length. 2. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 3, or the amino acid sequence that is at least 95% identical thereto. 3. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 4, or the amino acid sequence that is at least 95% identical thereto. 4. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 8, or the amino acid sequence that is at least 95% identical thereto. 5. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 9, or the amino acid sequence that is at least 95% identical thereto. 6. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 10, or the amino acid sequence that is at least 95% identical thereto. 7. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 11, or the amino acid sequence that is at least 95% identical thereto. 8. The method of claim 1 , wherein the subject is a human. 9. The method of claim 1 , wherein the composition is a pharmaceutical composition. 10. The method of claim 1 , wherein the composition is administered parenterally, subcutaneously, intravenously, intranasally, intraepidermally, intradermally, or intramuscularly.
Assignees
Inventors
Classifications
from Richettsiales (o) · CPC title
from ticks · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
- C07K16/1246Primary
Rickettsiales (O) · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10131705B2 cover?
- The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.
- Who is the assignee on this patent?
- Res Found Dev
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1246. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).